Simon&Co. Helps MD Drug Company Obtain FDA Approval of Orphan Drug to Treat Disfiguring Childhood Condition

Simon&Co. helped Nobelpharma America, a Maryland-based pharmaceutical and medical device company, obtain FDA approval of an orphan drug to treat tuberous sclerosis complex (TSC) facial angiofibroma, a disfiguring childhood condition. On April 4, 2022, the FDA approved HYFTOR™ as the first topical treatment for facial angiofibroma associated with TSC in adults and children six years of age or older. This is Nobelpharma’s first FDA approval, a key milestone for the company.